Compare CODA & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | MNOV |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.4M | 72.7M |
| IPO Year | 2007 | 2004 |
| Metric | CODA | MNOV |
|---|---|---|
| Price | $11.39 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 363.3K | 63.8K |
| Earning Date | 03-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,316,161.00 | $2,360,807.00 |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $12.62 | N/A |
| P/E Ratio | $144.38 | ★ N/A |
| Revenue Growth | 4.98 | ★ 194.15 |
| 52 Week Low | $5.76 | $1.13 |
| 52 Week High | $18.00 | $1.96 |
| Indicator | CODA | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 44.39 |
| Support Level | $7.47 | $1.22 |
| Resistance Level | $12.22 | $1.40 |
| Average True Range (ATR) | 1.03 | 0.06 |
| MACD | -0.40 | 0.01 |
| Stochastic Oscillator | 1.04 | 17.64 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.